Article Text

Download PDFPDF
The Use of Retinoids in Ovarian Cancer: A Review of the Literature
  1. Jenny M. Whitworth, MD*,
  2. J. Michael Straughn, MD*,
  3. Venkatram R. Atigadda, PhD,
  4. Donald D. Muccio, PhD and
  5. Donald J. Buchsbaum, PhD
  1. *Departments of Obstetrics and Gynecology,
  2. Departments of Chemistry, and
  3. Departments of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL.
  1. Address correspondence and reprint requests to Jenny M. Whitworth, MD, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Suite 10250, 1700 6th Ave S, Birmingham, AL 35233. E-mail:


Abstract Ovarian cancer is the deadliest of all gynecologic malignancies. The search for novel treatment modalities to augment traditional chemotherapy and improve quality of life is ongoing. Retinoids, a class of compounds composed of vitamin A, its natural derivatives, and synthetic analogs, have been studied extensively in both the prevention and treatment of gynecologic malignancies. In this article, we reviewed preclinical studies and clinical trials conducted using retinoids in ovarian cancer.

  • Retinoid
  • Ovarian cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare that there is no conflict of interest.